Kaigene Licenses Next-Generation FcRn Inhibitor KG006 to Taisho for Japan in Deal Worth Up to $351 Million
核心洞察
Kaigene grants Taisho Pharmaceutical exclusive rights to develop and commercialize FcRn (搜索) inhibitor KG006 (搜索) in Japan, receiving a $5 million upfront payment.
The deal includes up to $22 million plus ¥57.5 billion JPY (~$351 million) in milestone payments, plus tiered royalties on Japanese net sales.
The agreement establishes a three-way MRCT collaboration among Kaigene, Taisho, and Celltrion to accelerate global Phase 3 development of KG006 (搜索).
Kaigene, Inc. (搜索), a U.S.-based biotechnology company focused on next-generation antibody therapeutics for autoimmune disorders, has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. for the development and commercialization of its next-generation human neonatal Fc receptor (hFcRn) inhibitor, KG006 (搜索), in Japan. The agreement, announced on July 30, 2026, brings together three key players — Kaigene, Taisho, and Celltrion — in a coordinated global development effort.
Under the terms of the agreement, Kaigene will receive a one-time upfront payment of $5 million. The company is also eligible to receive up to a combined total of $22 million and ¥57.5 billion JPY (approximately $351 million) in aggregate development, regulatory, and sales milestone payments upon achievement of specific clinical, regulatory, and cumulative net sales milestones. Additionally, Kaigene will receive tiered royalties on net sales of the product in Japan. Taisho assumes full responsibility and holds exclusive rights for clinical development, regulatory approval, and commercialization of KG006 (搜索) within the Japanese territory.
A Three-Way Global Collaboration
This agreement complements Kaigene's existing global alliance with Celltrion Inc., which holds global development and commercialization rights to KG006 (搜索) outside of Greater China and Japan. Subject to further clinical and regulatory planning, the new partnership is expected to provide a collaborative framework for Taisho's participation in the planned Multi-Regional Clinical Trial (MRCT) Phase 3 study led by Celltrion. The three-way clinical development cooperation among Celltrion, Kaigene, and Taisho aims to streamline global clinical development and potentially accelerate the development timeline for KG006.
"We are thrilled to partner with Taisho, a company with an exceptional legacy and validated capabilities in successfully bringing advanced antibody therapeutics to patients," said Minjae Shin, Chief Executive Officer and Founder of Kaigene, Inc. (搜索) "In today's landscape, the ultimate key to success lies in uniting the unique strengths and complementary expertise of each partner to accelerate global clinical development and commercialization."
Shin further emphasized the strategic significance: "Following our deep alliance with Celltrion as our global development leader, the integration of Taisho as our definitive Japanese partner completes a formidable 'One Team.' This collective synergy will maximize the potential of KG006 (搜索) as a true best-in-class therapeutic in the global FcRn (搜索) market."
Taisho's Autoimmune Expertise
Taisho brings substantial biologics expertise to the alliance, with a proven track record in the autoimmune space. The company has extensive experience in the development and commercialization of Nanozora (搜索)®, an innovative anti-TNF VHH antibody therapeutic for the treatment of rheumatoid arthritis (搜索) in Japan. Through this strategic alliance, Taisho significantly bolsters its innovative autoimmune portfolio, while Kaigene secures an optimal local partner with deeply rooted clinical and commercialization capabilities and marketing infrastructure to ensure a rapid and successful market launch for KG006 (搜索) in Japan.
KG006 (搜索): A Next-Generation FcRn (搜索) Inhibitor
KG006 (搜索), also referred to by Celltrion as CT-P77, is a next-generation FcRn (搜索) inhibitor featuring a novel antibody structure. It is being developed as a potentially best-in-class therapeutic offering deep pathogenic antibody degradation, extended durability, and a convenient, patient-administered subcutaneous injection formulation. As a class, FcRn inhibitors possess significant market potential and commercial scalability across a broad spectrum of autoantibody-mediated autoimmune diseases (搜索).
Kaigene leverages its proprietary PDEG™ (Pathogenic Antibody Degrader) platform — a dual-acting technology optimized to selectively degrade pathogenic antibodies and suppress the B cells that produce autoantibodies. The company has consistently validated its immunology pipeline through consecutive high-profile global transactions, including a November 2025 global licensing agreement with Celltrion covering worldwide rights for KG002 and global rights excluding Japan and Greater China for KG006 (搜索).